Clinical evaluation of probucol in hypercholesterolemia: Individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression

Damiano Baldassarre, Guido Franceschini, Giulia Peruzzotti, Bruno Brusoni, Cesare R. Sirtori

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Probucol treatment has been evaluated in 140 patients with hypercholesterolemia attending a single Lipid Clinic, in an attempt to identify the relations between lipid/lipoprotein responses and patient characteristics. Probucol was administered as a single drug at the standard dose (0.5 g tables b.i.d.) for at least 6 months. One-hundred (71%) patients displayed a reduction of low-density lipoprotein cholesterol (LDL-C), which was significantly correlated with the baseline LDL-C level (r = 0.64; p <0.0001). Most of the patients (90%) also responded with a reduction of high- density lipoprotein cholesterol (HDL-C); the HDL-C reduction was also directly related to baseline HDL cholesterolemia (r = 0.67, p <0.0001). A highly significant correlation was found between the individual LDL-C and HDL-C responses. Eleven patients who continued with probucol treatment had a B-mode ultrasonographic investigation performed at baseline and after 24 months. No changes in carotid mean and maximal intimal-medial thickness were recorded, in contrast to an increase (i.e., indicative of atherosclerosis progression) in matched patients with hypercholesterolemia receiving other lipid-lowering regimens. Our report underlines that probucol can still provide a valuable option for the treatment for hypercholesterolemia, being particularly effective in patients with a combined increase of LDL-C and HDL- C levels.

Original languageEnglish
Pages (from-to)784-789
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume30
Issue number6
DOIs
Publication statusPublished - Dec 1997

Fingerprint

Probucol
Carotid Artery Diseases
Hypercholesterolemia
Lipoproteins
LDL Cholesterol
HDL Cholesterol
Lipids
Tunica Intima
Atherosclerosis
Therapeutics

Keywords

  • Carotid intimal-medial thickness
  • HDL cholesterol
  • Hypercholesterolemia
  • LDL cholesterol
  • Probucol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Clinical evaluation of probucol in hypercholesterolemia : Individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression. / Baldassarre, Damiano; Franceschini, Guido; Peruzzotti, Giulia; Brusoni, Bruno; Sirtori, Cesare R.

In: Journal of Cardiovascular Pharmacology, Vol. 30, No. 6, 12.1997, p. 784-789.

Research output: Contribution to journalArticle

@article{f7d932fa22494367974b677e16d41538,
title = "Clinical evaluation of probucol in hypercholesterolemia: Individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression",
abstract = "Probucol treatment has been evaluated in 140 patients with hypercholesterolemia attending a single Lipid Clinic, in an attempt to identify the relations between lipid/lipoprotein responses and patient characteristics. Probucol was administered as a single drug at the standard dose (0.5 g tables b.i.d.) for at least 6 months. One-hundred (71{\%}) patients displayed a reduction of low-density lipoprotein cholesterol (LDL-C), which was significantly correlated with the baseline LDL-C level (r = 0.64; p <0.0001). Most of the patients (90{\%}) also responded with a reduction of high- density lipoprotein cholesterol (HDL-C); the HDL-C reduction was also directly related to baseline HDL cholesterolemia (r = 0.67, p <0.0001). A highly significant correlation was found between the individual LDL-C and HDL-C responses. Eleven patients who continued with probucol treatment had a B-mode ultrasonographic investigation performed at baseline and after 24 months. No changes in carotid mean and maximal intimal-medial thickness were recorded, in contrast to an increase (i.e., indicative of atherosclerosis progression) in matched patients with hypercholesterolemia receiving other lipid-lowering regimens. Our report underlines that probucol can still provide a valuable option for the treatment for hypercholesterolemia, being particularly effective in patients with a combined increase of LDL-C and HDL- C levels.",
keywords = "Carotid intimal-medial thickness, HDL cholesterol, Hypercholesterolemia, LDL cholesterol, Probucol",
author = "Damiano Baldassarre and Guido Franceschini and Giulia Peruzzotti and Bruno Brusoni and Sirtori, {Cesare R.}",
year = "1997",
month = "12",
doi = "10.1097/00005344-199712000-00013",
language = "English",
volume = "30",
pages = "784--789",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Clinical evaluation of probucol in hypercholesterolemia

T2 - Individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression

AU - Baldassarre, Damiano

AU - Franceschini, Guido

AU - Peruzzotti, Giulia

AU - Brusoni, Bruno

AU - Sirtori, Cesare R.

PY - 1997/12

Y1 - 1997/12

N2 - Probucol treatment has been evaluated in 140 patients with hypercholesterolemia attending a single Lipid Clinic, in an attempt to identify the relations between lipid/lipoprotein responses and patient characteristics. Probucol was administered as a single drug at the standard dose (0.5 g tables b.i.d.) for at least 6 months. One-hundred (71%) patients displayed a reduction of low-density lipoprotein cholesterol (LDL-C), which was significantly correlated with the baseline LDL-C level (r = 0.64; p <0.0001). Most of the patients (90%) also responded with a reduction of high- density lipoprotein cholesterol (HDL-C); the HDL-C reduction was also directly related to baseline HDL cholesterolemia (r = 0.67, p <0.0001). A highly significant correlation was found between the individual LDL-C and HDL-C responses. Eleven patients who continued with probucol treatment had a B-mode ultrasonographic investigation performed at baseline and after 24 months. No changes in carotid mean and maximal intimal-medial thickness were recorded, in contrast to an increase (i.e., indicative of atherosclerosis progression) in matched patients with hypercholesterolemia receiving other lipid-lowering regimens. Our report underlines that probucol can still provide a valuable option for the treatment for hypercholesterolemia, being particularly effective in patients with a combined increase of LDL-C and HDL- C levels.

AB - Probucol treatment has been evaluated in 140 patients with hypercholesterolemia attending a single Lipid Clinic, in an attempt to identify the relations between lipid/lipoprotein responses and patient characteristics. Probucol was administered as a single drug at the standard dose (0.5 g tables b.i.d.) for at least 6 months. One-hundred (71%) patients displayed a reduction of low-density lipoprotein cholesterol (LDL-C), which was significantly correlated with the baseline LDL-C level (r = 0.64; p <0.0001). Most of the patients (90%) also responded with a reduction of high- density lipoprotein cholesterol (HDL-C); the HDL-C reduction was also directly related to baseline HDL cholesterolemia (r = 0.67, p <0.0001). A highly significant correlation was found between the individual LDL-C and HDL-C responses. Eleven patients who continued with probucol treatment had a B-mode ultrasonographic investigation performed at baseline and after 24 months. No changes in carotid mean and maximal intimal-medial thickness were recorded, in contrast to an increase (i.e., indicative of atherosclerosis progression) in matched patients with hypercholesterolemia receiving other lipid-lowering regimens. Our report underlines that probucol can still provide a valuable option for the treatment for hypercholesterolemia, being particularly effective in patients with a combined increase of LDL-C and HDL- C levels.

KW - Carotid intimal-medial thickness

KW - HDL cholesterol

KW - Hypercholesterolemia

KW - LDL cholesterol

KW - Probucol

UR - http://www.scopus.com/inward/record.url?scp=0031425143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031425143&partnerID=8YFLogxK

U2 - 10.1097/00005344-199712000-00013

DO - 10.1097/00005344-199712000-00013

M3 - Article

C2 - 9436818

AN - SCOPUS:0031425143

VL - 30

SP - 784

EP - 789

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 6

ER -